Last reviewed · How we verify
FOSAMPRENAVIR CALCIUM
At a glance
| Generic name | FOSAMPRENAVIR CALCIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
Common side effects
- Skin rash
- Diarrhea
- Nausea
- Serum lipase elevation (> 2 x ULN)
- ALT elevation (> 5 x ULN)
- Vomiting
- AST elevation (> 5 x ULN)
- Triglycerides elevation (> 750 mg/dL)
- Headache
- Neutrophil count absolute (< 750 cells/mm³)
Key clinical trials
- Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction (PHASE2)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Oral Fosamprenavir + Sodium Alginate for GERD (PHASE2)
- Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (PHASE2)
- Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People (NA)
- Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOSAMPRENAVIR CALCIUM CI brief — competitive landscape report
- FOSAMPRENAVIR CALCIUM updates RSS · CI watch RSS